Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of TERT DNA and Electroporation With and Without IL-12 DNA for Patients With Breast, Lung, or Pancreatic Cancer at High Risk of Relapse Post Definitive Surgery and Adjuvant Therapy

Next Previous
X
Search
Trial Profile

Phase I Study of TERT DNA and Electroporation With and Without IL-12 DNA for Patients With Breast, Lung, or Pancreatic Cancer at High Risk of Relapse Post Definitive Surgery and Adjuvant Therapy

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs INO 1400 (Primary) ; INO 9012
  • Indications Breast cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Liver cancer; Lung cancer; Ovarian cancer; Pancreatic cancer
  • Focus Adverse reactions; First in man
  • Sponsors Inovio Pharmaceuticals

    • Most Recent Events

    • 10 Nov 2017 Interim results presented at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting 2017, according to an Inovio Pharmaceuticals media release.
    • 14 Jun 2016 Planned End Date changed from 1 Dec 2016 to 1 Apr 2018, as reported by ClinicalTrials.gov.
    • 14 Jun 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top